阿托伐他汀联合艾司洛尔治疗冠心病心绞痛患者对心功能、血脂及炎症指标的影响

Effects of Atorvastatin Combined with Esmolol on Cardiac Function,Blood Lipids and Inflammation Indexes in Patients with Coronary Heart Disease and Angina Pectoris

目的探讨阿托伐他汀联合艾司洛尔治疗对冠心病心绞痛患者心功能、血脂及炎症指标的影响。方法回顾性分析2017年2月—2018年4月收治的冠心病心绞痛112例的临床资料,按治疗方法分为观察组和对照组,每组56例。对照组给予艾司洛尔治疗,观察组在对照组基础上给予阿托伐他汀治疗。比较2组临床疗效、不良反应发生情况及治疗前后症状缓解情况、心功能指标、血脂指标和炎症指标变化。结果观察组总有效率高于对照组(P <0. 05)。治疗后2组心绞痛症状均较治疗前改善,且观察组较对照组改善明显(P <0. 05,P <0. 01)。治疗后2组左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)均低于治疗前,左心室射血分数(LVEF)均高于治疗前,且观察组LVESV、LVEDV水平低于对照组,LVEF高于对照组(P <0. 05,P <0. 01)。治疗后2组低密度脂蛋白胆固醇、胆固醇、甘油三酯、超敏C反应蛋白、肿瘤坏死因子-α、白介素-6水平均低于治疗前,且观察组低于对照组(P <0. 05,P <0. 01)。2组不良反应发生率比较差异无统计学意义(P> 0. 05)。结论阿托伐他汀联合艾司洛尔治疗冠心病心绞痛临床疗效显著,可有效改善临床症状、心功能,降低血脂及炎症指标水平。

Objective To explore effect of Atorvastatin combined with Esmolol on cardiac function, blood lipid and inflammatory indexes in patients with coronary heart disease and angina pectoris. Methods Clinical data of 112 patients with coronary heart disease and angina pectoris admitted during February 2017 and April 2018 was retrospectively analyzed, and the patients were divided into observation group and control group according to therapeutic method ( n =56 in each group). Control group was treated with Esmolol, while observation group was added with Atorvastatin. Curative effect, incidence rate of adverse reactions, conditions of symptom relief, changes of cardiac function indexes, blood lipid and inflammatory indexes before and after treatment were compared in two groups. Results The total effective rate in observation group was significantly higher than that in control group( P <0.05). After treatment, symptoms of angina pectoris were significantly improved compared with those before treatment in two groups, and the improvement in observation group was more obvious than that in control group ( P <0.05, P <0.01). After treatment, left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) levels were significantly lower, while left ventricular ejection fraction (LVEF) levels were significantly higher than those before treatment in two groups;levels of LVESV and LVEDV in observation group were significantly lower, while LVEF level was significantly higher than those in control group ( P <0.05, P <0.01). After treatment, levels of low density lipoprotein cholesterol (LDL-ch), cholesterol, triglyceride, hypersensitive C-reactive protein, tumor necrosis factor-α and interleukin-6 were significantly lower than those before treatment in two groups, and the levels in observation group were significantly lower than those in control group ( P <0.05 , P <0.01). There was no significant difference in incidence rate of adverse reactions between two groups ( P > 0.05). Conclusion Atorvastatin combined with Esmolol has significantly clinical effect in treatment of patients with coronary heart disease and angina pectoris, and it may effectively improve clinical symptoms, cardiac function and reduce levels of blood lipid and inflammatory indexes.